Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.

MLA

Nguyen, Nga, et al. “Influence of Melanoma Type on Incidence and Downstream Implications of Cutaneous Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.” Journal of the American Academy of Dermatology, vol. 88, no. 6, June 2023, pp. 1308–16. EBSCOhost, https://doi.org/10.1016/j.jaad.2023.02.014.

APA

Nguyen, N., Wan, G., Ugwu-Dike, P., Alexander, N. A., Raval, N., Zhang, S., Jairath, R., Phillipps, J., Leung, B., Roster, K., Seo, J., Lu, C., Tang, K., Choi, M. S., DeSimone, M. S., Theodosakis, N., Amadife, M., Cox, N., Le, T. K., & Liu, F. (2023). Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. Journal of the American Academy of Dermatology, 88(6), 1308–1316. https://doi.org/10.1016/j.jaad.2023.02.014

Chicago

Nguyen, Nga, Guihong Wan, Pearl Ugwu-Dike, Nora A. Alexander, Neel Raval, Shijia Zhang, Ruple Jairath, et al. 2023. “Influence of Melanoma Type on Incidence and Downstream Implications of Cutaneous Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.” Journal of the American Academy of Dermatology 88 (6): 1308–16. doi:10.1016/j.jaad.2023.02.014.